Novo Nordisk A/S (NYSE:NVO – Get Rating) has been given a consensus recommendation of “Buy” by the nineteen research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $557.80.
Several analysts have commented on the stock. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Novo Nordisk A/S from 850.00 to 900.00 in a report on Wednesday, May 4th. Liberum Capital lowered shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a report on Tuesday, January 25th. StockNews.com initiated coverage on shares of Novo Nordisk A/S in a report on Thursday, March 31st. They set a “strong-buy” rating for the company. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $104.00 target price for the company in a report on Friday, February 25th. Finally, Cowen upgraded shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Monday, April 25th.
A number of large investors have recently bought and sold shares of the business. Mathes Company Inc. purchased a new stake in shares of Novo Nordisk A/S in the 4th quarter worth $1,930,000. Ahrens Investment Partners LLC purchased a new stake in Novo Nordisk A/S in the fourth quarter worth about $25,000. Farmers & Merchants Investments Inc. bought a new position in shares of Novo Nordisk A/S in the first quarter worth about $26,000. Cornerstone Advisory LLC bought a new position in shares of Novo Nordisk A/S in the fourth quarter worth about $28,000. Finally, Bell Investment Advisors Inc bought a new position in shares of Novo Nordisk A/S in the third quarter worth about $28,000.
Novo Nordisk A/S (NYSE:NVO – Get Rating) last issued its quarterly earnings data on Friday, April 29th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.85 by $0.09. Novo Nordisk A/S had a net margin of 33.16% and a return on equity of 72.67%. The business had revenue of $6.34 billion during the quarter, compared to analyst estimates of $5.82 billion. Sell-side analysts forecast that Novo Nordisk A/S will post 3.38 earnings per share for the current year.
The business also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 5th. Shareholders of record on Monday, March 28th were given a $0.741 dividend. This represents a yield of 1.1%. The ex-dividend date of this dividend was Friday, March 25th. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.56. Novo Nordisk A/S’s payout ratio is 44.05%.
About Novo Nordisk A/S (Get Rating)
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.
- Get a free copy of the StockNews.com research report on Novo Nordisk A/S (NVO)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.